BR9916288A - Clatratos de deidroepiandroesterona e correspondentes composições farmacêuticas - Google Patents

Clatratos de deidroepiandroesterona e correspondentes composições farmacêuticas

Info

Publication number
BR9916288A
BR9916288A BR9916288-1A BR9916288A BR9916288A BR 9916288 A BR9916288 A BR 9916288A BR 9916288 A BR9916288 A BR 9916288A BR 9916288 A BR9916288 A BR 9916288A
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
clathrates
dehydroepianderesterone
corresponding pharmaceutical
dehydropianderesterone
Prior art date
Application number
BR9916288-1A
Other languages
English (en)
Inventor
Paolo Corvi Mora
Original Assignee
Euphar Group Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euphar Group Srl filed Critical Euphar Group Srl
Publication of BR9916288A publication Critical patent/BR9916288A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

<B>"CLATRATOS DE DEIDROEPIANDROESTERONA E CORRESPONDENTES COMPOSIçõES FARMACêUTICAS"<D> A presente invenção se refere a clatrados de deidropiandroesterona, possivelmente na forma de sulfato, em uma matriz consistindo de uma ciclodextrina e opcionalmente compreendendo um agente de co-solubilização e às correspondentes composições farmacêuticas adequadas para terapia de substituição, para o tratamento de insuficiência adrenocortical.
BR9916288-1A 1998-12-18 1999-12-16 Clatratos de deidroepiandroesterona e correspondentes composições farmacêuticas BR9916288A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998MI002745A IT1304190B1 (it) 1998-12-18 1998-12-18 Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
PCT/EP1999/010010 WO2000037109A2 (en) 1998-12-18 1999-12-16 Clathrates of dehydroepiandrosterone and corresponding pharmaceutical compositions

Publications (1)

Publication Number Publication Date
BR9916288A true BR9916288A (pt) 2001-10-16

Family

ID=11381280

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9916288-1A BR9916288A (pt) 1998-12-18 1999-12-16 Clatratos de deidroepiandroesterona e correspondentes composições farmacêuticas

Country Status (24)

Country Link
EP (1) EP1140110B1 (pt)
JP (1) JP2002532565A (pt)
KR (1) KR100693514B1 (pt)
CN (1) CN1198620C (pt)
AR (1) AR021663A1 (pt)
AT (1) ATE243517T1 (pt)
AU (1) AU759979B2 (pt)
BR (1) BR9916288A (pt)
CA (1) CA2355148A1 (pt)
CO (1) CO5231137A1 (pt)
DE (1) DE69909128T2 (pt)
DK (1) DK1140110T3 (pt)
EA (1) EA003304B1 (pt)
ES (1) ES2203232T3 (pt)
HU (1) HU225414B1 (pt)
IL (2) IL143776A0 (pt)
IT (1) IT1304190B1 (pt)
NZ (1) NZ512795A (pt)
PE (1) PE20001379A1 (pt)
PT (1) PT1140110E (pt)
TR (1) TR200101766T2 (pt)
TW (1) TWI225791B (pt)
WO (1) WO2000037109A2 (pt)
ZA (1) ZA200105223B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2815860B1 (fr) * 2000-10-26 2003-12-12 Oreal Composition, notamment cosmetique, comprenant la dhea et/ou precurseur ou derive de celle-ci et au moins un agent myorelaxant
EP1285927A3 (de) * 2001-08-16 2005-06-29 Schering Aktiengesellschaft Verwendung von Glucocorticoid-Rezeptorantagonisten zur Vorbeugung und Behandlung von Erkrankungen des männlichen Reproduktionssystems
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
ITMI20022549A1 (it) * 2002-12-02 2004-06-03 Actimex S R L Composizione quaternaria comprendente come sostanza attiva la propolis.
US20070191404A1 (en) 2004-04-01 2007-08-16 Pierre Bartsch Pharmaceutical compositions of pyrimidine-2,4,6-triones
WO2006137433A1 (ja) * 2005-06-21 2006-12-28 Wakamoto Pharmaceutical Co., Ltd. レボカバスチンを可溶化させた水性薬剤
ITPD20050224A1 (it) * 2005-07-19 2007-01-20 Actimex Srl Composizioni contenenti micronutrienti aventi in particolare attivita' antiossidante e loro impiego
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
ES2545337T3 (es) * 2011-07-19 2015-09-10 Pantarhei Bioscience B.V. Comprimido que contiene dehidroepiandrosterona (DHEA)
DE102012101680A1 (de) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
EP2986634B1 (en) * 2013-04-19 2019-11-20 University of Houston System Cocrystalline dhea formulations
EP3505154B1 (en) 2017-12-26 2022-04-06 Industrial Technology Research Institute Composition for improving the solubility of poorly soluble substances, use thereof and complex formulation containing thereof
EP3666260A1 (en) 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2647343B1 (fr) * 1989-05-24 1994-05-06 Rhone Poulenc Sante Nouvelle forme pharmaceutique poreuse et sa preparation
US4978532A (en) * 1989-08-11 1990-12-18 Pharmedic Co. Dosage form for administration of dehydroepiandrosterone
US5120720A (en) * 1990-09-20 1992-06-09 The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers
WO1994004155A1 (en) * 1992-08-19 1994-03-03 Health Resource Institute, Ltd. Dehydroepiandrosterone therapy for the treatment of eye disorders
WO1995015746A1 (en) * 1993-12-10 1995-06-15 The School Of Pharmacy Liposome delivery systems
CN1201397A (zh) * 1995-11-13 1998-12-09 萨珀根公司 甾族化合物给药的改进配方

Also Published As

Publication number Publication date
WO2000037109A3 (en) 2000-09-14
PT1140110E (pt) 2003-11-28
ITMI982745A1 (it) 2000-06-18
AU1981000A (en) 2000-07-12
TWI225791B (en) 2005-01-01
ZA200105223B (en) 2002-09-25
IT1304190B1 (it) 2001-03-08
DE69909128T2 (de) 2004-05-06
DK1140110T3 (da) 2003-10-20
TR200101766T2 (tr) 2001-12-21
ES2203232T3 (es) 2004-04-01
CN1333686A (zh) 2002-01-30
HU225414B1 (en) 2006-11-28
AR021663A1 (es) 2002-07-31
NZ512795A (en) 2003-08-29
IL143776A (en) 2007-03-08
WO2000037109A2 (en) 2000-06-29
HUP0104822A2 (hu) 2002-05-29
KR20010086109A (ko) 2001-09-07
CO5231137A1 (es) 2002-12-27
CA2355148A1 (en) 2000-06-29
EA200100674A1 (ru) 2001-12-24
IL143776A0 (en) 2002-04-21
EP1140110B1 (en) 2003-06-25
AU759979B2 (en) 2003-05-01
CN1198620C (zh) 2005-04-27
PE20001379A1 (es) 2000-11-25
EP1140110A2 (en) 2001-10-10
HUP0104822A3 (en) 2002-08-28
JP2002532565A (ja) 2002-10-02
ATE243517T1 (de) 2003-07-15
DE69909128D1 (de) 2003-07-31
KR100693514B1 (ko) 2007-03-14
EA003304B1 (ru) 2003-04-24

Similar Documents

Publication Publication Date Title
BR9916288A (pt) Clatratos de deidroepiandroesterona e correspondentes composições farmacêuticas
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
ES2162319T3 (es) Uso del agente quelante clioquinol para la fabricacion de una composicion farmaceutica para el tratamiento de la enfermedad de alzheimer.
BR0109131A (pt) Fator viii modificado
BRPI0515684A (pt) formulações de cristais injetáveis ativas de longa duração de metabólitos de estradiol, e métodos de utilização das mesmas
BR0113184A (pt) Implante artificial e processo para produzir o mesmo
DE69636989D1 (de) Bioaktive lasttragende zusammensetzungen zum knochenverbund
BR0107869A (pt) Composições farmacêuticas eletrogiradas
GB0108592D0 (en) Therapeutic agents
DE50203788D1 (de) Pharmazeutische zusammensetzung zur ophtalmologischen und rhinologischen anwendung
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
BRPI0408655A (pt) formulações compreendendo um agente ativo e cacau em pó e a sua utilização
DE60134274D1 (en) Complex enthaltend modafinil und cyclodextrin
BR0012696A (pt) Composição oftálmica
BR0208727A (pt) Eritropoietina melhorando a toxicidade in vivo induzida por quimioterapia
WO2008105808A3 (en) FORMULATIONS OF RADIOPROTECTIVE α, β UNSATURATED ARYL SULFONES
BR0011064A (pt) Processo para a preparação de um poliol, e, composição de poliol
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
BR0309113A (pt) Composições farmacêuticas de liberação controlada de carbidopa e levodopa e processo para a preparação das mesmas
AR047480A1 (es) Composicion para la prevencion y/o tratamiento de enfermedades metabolicas oseas; proceso de preparacion y uso de esta composicion
AU4789099A (en) Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents
TR200200278T2 (tr) Kalsilitik bileşimler
BR0009194A (pt) Composição do resorcinol
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
BR0210063A (pt) Composição estável e uso da mesma

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.

B15K Others concerning applications: alteration of classification

Ipc: B82Y 5/00 (2011.01), A61K 31/565 (2006.0